Michela R.
- Country
- Italy
- Department
- Haematology Unit
Research Overview
- (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis
- Phase 3 Randomized Trial of Cytarabine, Midostaurin, and Daunorubicin Hydrochloride in FLT3-Mutated Acute Myeloid Leukemia with Peripheral Blast Clearance
- Evaluation of RVU120 Monotherapy in Relapsed/Refractory High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with/without NPM1 Mutation
Data & Insights
Has run more than one trial at 70 of 142 partner sites.
Specializations
Haematologic Malignancies
Michela Rondoni’s clinical research activity is strongly centred on acute myeloid leukemia, acute lymphoblastic leukemia, and a broad range of lymphoid neoplasms, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, and peripheral T-cell lymphoma.
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Chronic lymphocytic leukemia
- Multiple myeloma
- Myelodysplastic syndromes
The investigator is also involved in studies addressing multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and related hematologic malignancies requiring targeted and immune-based treatment strategies.
Solid Tumours in Thoracic and Digestive Oncology
Another major area of interest is non-small cell lung cancer, with activity spanning EGFR-mutated, ALK-positive, ROS1-positive, and KRAS G12C-mutated disease, as well as locally advanced and metastatic presentations.
- Non-small cell lung cancer
- Small-cell lung cancer
- Head and neck squamous cell carcinoma
- Colorectal cancer
- Gastric and gastroesophageal cancer
Her portfolio also includes colorectal cancer, gastric and gastroesophageal cancer, biliary tract cancers, pancreatic cancer, and head and neck squamous cell carcinoma, reflecting a strong focus on advanced solid tumours.
Breast and Gynecologic Oncology
Michela Rondoni is engaged in research on breast cancer across early and advanced settings, including HER2-positive, hormone receptor-positive, and triple-negative breast cancer, with attention to recurrence and metastatic disease.
- Breast cancer
- Triple-negative breast cancer
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
Her therapeutic scope also covers ovarian cancer, endometrial cancer, cervical cancer, and fallopian tube neoplasms, with interest in both recurrent and high-risk disease states.
Inflammatory, Autoimmune, and Rare Disorders
Beyond oncology, the investigator contributes to studies in juvenile idiopathic arthritis, recurrent pericarditis, and relapsing multiple sclerosis, indicating involvement in immune-mediated conditions requiring targeted therapeutic approaches.
- Juvenile idiopathic arthritis
- Recurrent pericarditis
- Multiple sclerosis
- Idiopathic pulmonary fibrosis
- Systemic mastocytosis
Additional activity includes idiopathic pulmonary fibrosis, systemic mastocytosis, and other uncommon immune and inflammatory conditions, broadening the therapeutic landscape beyond cancer.
Cardiovascular and Thromboembolic Disease
Her research profile also includes atrial fibrillation, acute coronary syndrome, heart failure, ischemic stroke, and venous thromboembolism, with emphasis on conditions where prevention and risk reduction are central therapeutic goals.
- Atrial fibrillation
- Heart failure
- Ischemic stroke
- Venous thromboembolism
- Atherosclerotic cardiovascular disease
Her involvement extends to atherosclerotic cardiovascular disease, myocardial infarction, and thrombosis-related prevention strategies in complex patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.